What does Akeso's primo plenary spot say about its survival data?

Summary: People on Wall Street are buzzing about a new lung cancer drug called ivonescimab, made by the companies Akeso and Summit Therapeutics. Everyone is trying to guess what the drug's survival data will show at the big American Society of Clinical Oncology meeting next month. The drug got a top presentation spot at the meeting, which makes the mystery even more exciting! Meanwhile, the author reporting the news is just trying to survive his own spring allergies and a bad head cold.

For more details, see rssapp-statnews-com at statnews.com/2026/04/30/akeso-summit-therapeutics-drug-ivonescimab-results-announced-asco/ (opens in new tab)